{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:38:36Z","timestamp":1788863916506,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:00:00Z","timestamp":1225152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1038\/ncpneph0977","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T13:23:44Z","timestamp":1225200224000},"page":"24-33","source":"Crossref","is-referenced-by-count":45,"title":["Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?"],"prefix":"10.1038","volume":"5","author":[{"given":"James B","family":"Wetmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Darryl","family":"Quarles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,28]]},"reference":[{"key":"BFncpneph0977_CR1","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.01150308","volume":"3","author":"W Al-Badr","year":"2008","unstructured":"Al-Badr W and Martin KJ (2008) Vitamin D and kidney disease. Clin J Am Soc Nephrol 3: 1555\u20131560","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0977_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ncpendmet0394","volume":"3","author":"AJ Brown","year":"2007","unstructured":"Brown AJ and Slatopolsky E (2007) Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab 3: 134\u2013144","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"BFncpneph0977_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2215\/CJN.05781207","volume":"3","author":"R Mehrotra","year":"2008","unstructured":"Mehrotra R et al. (2008) Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3: 1144\u20131151","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0977_CR4","doi-asserted-by":"publisher","first-page":"c109","DOI":"10.1159\/000108652","volume":"107","author":"D Zehnder","year":"2007","unstructured":"Zehnder D et al. (2007) Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract 107: c109\u2013c116","journal-title":"Nephron Clin Pract"},{"key":"BFncpneph0977_CR5","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1053\/ajkd.2001.20740","volume":"37","author":"E Slatopolsky","year":"2001","unstructured":"Slatopolsky E et al. (2001) Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37: S54\u2013S57","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/154411130401500503","volume":"15","author":"PS Rowe","year":"2004","unstructured":"Rowe PS (2004) The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15: 264\u2013281","journal-title":"Crit Rev Oral Biol Med"},{"key":"BFncpneph0977_CR7","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1074\/jbc.M207872200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H et al. (2003) Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278: 2206\u20132211","journal-title":"J Biol Chem"},{"key":"BFncpneph0977_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S et al. (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305\u20131315","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T et al. (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195: 125\u2013131","journal-title":"J Endocrinol"},{"key":"BFncpneph0977_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429\u2013435","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0977_CR11","doi-asserted-by":"publisher","first-page":"F1577","DOI":"10.1152\/ajprenal.00463.2006","volume":"293","author":"F Perwad","year":"2007","unstructured":"Perwad F et al. (2007) Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293: F1577\u2013F1583","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFncpneph0977_CR12","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","volume":"64","author":"T Larsson","year":"2003","unstructured":"Larsson T et al. (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272\u20132279","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O et al. (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205\u20132215","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","volume":"44","author":"T Shigematsu","year":"2004","unstructured":"Shigematsu T et al. (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250\u2013256","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584\u2013592","journal-title":"N Engl J Med"},{"key":"BFncpneph0977_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1681\/ASN.2007060673","volume":"19","author":"T Isakova","year":"2008","unstructured":"Isakova T et al. (2008) Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19: 615\u2013623","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770\u2013774","journal-title":"Nature"},{"key":"BFncpneph0977_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1006\/bbrc.2000.4226","volume":"280","author":"N Koh","year":"2001","unstructured":"Koh N et al. (2001) Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280: 1015\u20131020","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 1","key":"BFncpneph0977_CR19","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/j.1744-9987.2005.00302.x","volume":"9","author":"M Tokumoto","year":"2005","unstructured":"Tokumoto M et al. (2005) Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther Apher Dial 9 (Suppl 1): S27\u2013S34","journal-title":"Ther Apher Dial"},{"key":"BFncpneph0977_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI113172","volume":"80","author":"AA Portale","year":"1987","unstructured":"Portale AA et al. (1987) Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 80: 1147\u20131154","journal-title":"J Clin Invest"},{"key":"BFncpneph0977_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","volume":"43","author":"JW Coburn","year":"2004","unstructured":"Coburn JW et al. (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877\u2013890","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR22","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","volume":"70","author":"F Tentori","year":"2006","unstructured":"Tentori F et al. (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858\u20131865","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P et al. (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3: 36\u201345","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0977_CR24","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516\u20131525","journal-title":"N Engl J Med"},{"key":"BFncpneph0977_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","volume":"81","author":"EM Brown","year":"2001","unstructured":"Brown EM and MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239\u2013297","journal-title":"Physiol Rev"},{"key":"BFncpneph0977_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/ncpendmet0388","volume":"3","author":"EM Brown","year":"2007","unstructured":"Brown EM (2007) Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3: 122\u2013133","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"BFncpneph0977_CR27","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1111\/j.1523-1755.2005.09501.x","volume":"95","author":"J Silver","year":"2005","unstructured":"Silver J and Levi R (2005) Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 95: S8\u2013S12","journal-title":"Kidney Int Suppl"},{"key":"BFncpneph0977_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/0092-8674(93)90617-Y","volume":"75","author":"MR Pollak","year":"1993","unstructured":"Pollak MR et al. (1993) Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297\u20131303","journal-title":"Cell"},{"key":"BFncpneph0977_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/ng1295-389","volume":"11","author":"C Ho","year":"1995","unstructured":"Ho C et al. (1995) A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 11: 389\u2013394","journal-title":"Nat Genet"},{"key":"BFncpneph0977_CR30","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1210\/endo.139.10.6262","volume":"139","author":"YC Li","year":"1998","unstructured":"Li YC et al. (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139: 4391\u20134396","journal-title":"Endocrinology"},{"key":"BFncpneph0977_CR31","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/ndt\/gfm177","volume":"22","author":"T Drueke","year":"2007","unstructured":"Drueke T et al. (2007) Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 22: 1828\u20131839","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0977_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/01.mnh.0000172722.52499.71","volume":"14","author":"WG Goodman","year":"2005","unstructured":"Goodman WG (2005) Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Curr Opin Nephrol Hypertens 14: 355\u2013360","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFncpneph0977_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1172\/JCI17416","volume":"111","author":"CH Kos","year":"2003","unstructured":"Kos CH et al. (2003) The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111: 1021\u20131028","journal-title":"J Clin Invest"},{"key":"BFncpneph0977_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1172\/JCI200317054","volume":"111","author":"Q Tu","year":"2003","unstructured":"Tu Q et al. (2003) Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 111: 1029\u20131037","journal-title":"J Clin Invest"},{"key":"BFncpneph0977_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","volume":"67","author":"M Colloton","year":"2005","unstructured":"Colloton M et al. (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism? Kidney Int 67: 467\u2013476","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","volume":"11","author":"J Chin","year":"2000","unstructured":"Chin J et al. (2000) Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 11: 903\u2013911","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR37","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1093\/ndt\/gfn191","volume":"23","author":"AL de Francisco","year":"2008","unstructured":"de Francisco AL et al. (2008) Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 23: 2895\u20132901","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0977_CR38","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2215\/CJN.04150907","volume":"3","author":"C Lomonte","year":"2008","unstructured":"Lomonte C et al. (2008) Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism. Clin J Am Soc Nephrol 3: 794\u2013799","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0977_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1523-1755.1999.00230.x","volume":"55","author":"H Matsushita","year":"1999","unstructured":"Matsushita H et al. (1999) Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int 55: 130\u2013138","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ki.1997.41","volume":"51","author":"J Gogusev","year":"1997","unstructured":"Gogusev J et al. (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51: 328\u2013336","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR41","first-page":"1598","volume":"81","author":"O Kifor","year":"1996","unstructured":"Kifor O et al. (1996) Reduced immunostaining for the extracellular Ca2-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598\u20131606","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0977_CR42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1046\/j.1523-1755.1999.00386.x","volume":"55","author":"AJ Brown","year":"1999","unstructured":"Brown AJ et al. (1999) Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 55: 1284\u20131292","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR43","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1046\/j.1523-1755.2001.00027.x","volume":"60","author":"CS Ritter","year":"2001","unstructured":"Ritter CS et al. (2001) Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60: 1737\u20131744","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2559.1998.00459.x","volume":"33","author":"LN Martin","year":"1998","unstructured":"Martin LN et al. (1998) Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis. Histopathology 33: 46\u201351","journal-title":"Histopathology"},{"key":"BFncpneph0977_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1172\/JCI116720","volume":"92","author":"N Fukuda","year":"1993","unstructured":"Fukuda N et al. (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436\u20131443","journal-title":"J Clin Invest"},{"key":"BFncpneph0977_CR46","first-page":"410","volume":"114","author":"X Wang","year":"2001","unstructured":"Wang X et al. (2001) Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Chin Med J (Engl) 114: 410\u2013414","journal-title":"Chin Med J (Engl)"},{"key":"BFncpneph0977_CR47","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/j.1523-1755.2002.kid585.x","volume":"62","author":"M Tokumoto","year":"2002","unstructured":"Tokumoto M et al. (2002) Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62: 1196\u20131207","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1530\/eje.0.1480403","volume":"148","author":"S Yano","year":"2003","unstructured":"Yano S et al. (2003) Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol 148: 403\u2013411","journal-title":"Eur J Endocrinol"},{"key":"BFncpneph0977_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jsbmb.2006.11.012","volume":"103","author":"A Maiti","year":"2007","unstructured":"Maiti A and Beckman MJ (2007) Extracellular calcium is a direct effecter of VDR levels in proximal tubule epithelial cells that counter-balances effects of PTH on renal Vitamin D metabolism. J Steroid Biochem Mol Biol 103: 504\u2013508","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncpneph0977_CR50","first-page":"F454","volume":"270","author":"AJ Brown","year":"1996","unstructured":"Brown AJ et al. (1996) Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 270: F454\u2013F460","journal-title":"Am J Physiol"},{"key":"BFncpneph0977_CR51","doi-asserted-by":"publisher","first-page":"30337","DOI":"10.1074\/jbc.M201804200","volume":"277","author":"L Canaff","year":"2002","unstructured":"Canaff L and Hendy GN (2002) Human calcium-sensing receptor gene: vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 277: 30337\u201330350","journal-title":"J Biol Chem"},{"key":"BFncpneph0977_CR52","unstructured":"Fishbane S et al.: Cinacalcet HCl with low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients versus vitamin D alone\u2014the ACHIEVE study. Clin J Am Soc Nephrol, in press"},{"key":"BFncpneph0977_CR53","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD et al. (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575\u2013583","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"JS Lindberg","year":"2003","unstructured":"Lindberg JS et al. (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248\u2013254","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","volume":"47","author":"GF Strippoli","year":"2006","unstructured":"Strippoli GF et al. (2006) Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47: 715\u2013726","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M et al. (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23: 328\u2013335","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0977_CR57","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","volume":"23","author":"GA Block","year":"2008","unstructured":"Block GA et al. (2008) Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23: 2311\u20132318","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0977_CR58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2215\/CJN.00870805","volume":"1","author":"GM Chertow","year":"2006","unstructured":"Chertow GM et al. (2006) Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 1: 305\u2013312","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0977_CR59","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ et al. (1998) 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427\u20131432","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR60","first-page":"301","volume":"54","author":"JA Delmez","year":"2000","unstructured":"Delmez JA et al. (2000) A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Clin Nephrol 54: 301\u2013308","journal-title":"Clin Nephrol"},{"key":"BFncpneph0977_CR61","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","volume":"40","author":"DW Coyne","year":"2002","unstructured":"Coyne DW et al. (2002) Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40: 1283\u20131288","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5414\/CNP65335","volume":"65","author":"HE Joist","year":"2006","unstructured":"Joist HE et al. (2006) Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol 65: 335\u2013341","journal-title":"Clin Nephrol"},{"key":"BFncpneph0977_CR63","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM et al. (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483\u20131490","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000168465","volume":"12","author":"L Brandi","year":"1992","unstructured":"Brandi L et al. (1992) Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 12: 311\u2013318","journal-title":"Am J Nephrol"},{"key":"BFncpneph0977_CR65","first-page":"315","volume":"56","author":"J Lindberg","year":"2001","unstructured":"Lindberg J et al. (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56: 315\u2013323","journal-title":"Clin Nephrol"},{"issue":"Suppl 10","key":"BFncpneph0977_CR66","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/ndt\/17.suppl_10.28","volume":"17","author":"T Akizawa","year":"2002","unstructured":"Akizawa T et al. (2002) Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients: one-year administration study. Nephrol Dial Transplant 17 (Suppl 10): S28\u2013S36","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0977_CR67","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446\u2013456","journal-title":"N Engl J Med"},{"key":"BFncpneph0977_CR68","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115\u20131125","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0977_CR69","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.ki.5001514","volume":"70","author":"K Kalantar-Zadeh","year":"2006","unstructured":"Kalantar-Zadeh K et al. (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771\u2013780","journal-title":"Kidney Int"},{"key":"BFncpneph0977_CR70","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","volume":"38","author":"SM Sprague","year":"2001","unstructured":"Sprague SM et al. (2001) Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38: S51\u2013S56","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR71","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607\u2013617","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0977_CR72","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"PT Liu","year":"2006","unstructured":"Liu PT et al. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770\u20131773","journal-title":"Science"},{"key":"BFncpneph0977_CR73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/BOR.0b013e32818e9d58","volume":"19","author":"DD Bikle","year":"2007","unstructured":"Bikle DD (2007) What is new in vitamin D: 2006\u20132007. Curr Opin Rheumatol 19: 383\u2013388","journal-title":"Curr Opin Rheumatol"},{"key":"BFncpneph0977_CR74","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1365-2362.2005.01487.x","volume":"35","author":"M Peterlik","year":"2005","unstructured":"Peterlik M and Cross HS (2005) Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 35: 290\u2013304","journal-title":"Eur J Clin Invest"},{"key":"BFncpneph0977_CR75","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2165\/00003495-200767140-00003","volume":"67","author":"D Andress","year":"2007","unstructured":"Andress D (2007) Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 67: 1999\u20132012","journal-title":"Drugs"},{"key":"BFncpneph0977_CR76","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245\u2013252","journal-title":"Kidney Int"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0977","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T01:46:46Z","timestamp":1709344006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,28]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["BFncpneph0977"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0977","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,28]]}}}